<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05009797</url>
  </required_header>
  <id_info>
    <org_study_id>2018_83</org_study_id>
    <secondary_id>2020-A02171-38</secondary_id>
    <nct_id>NCT05009797</nct_id>
  </id_info>
  <brief_title>PROSPective Evaluation of Outcome After CatheTer Ablation in Atrial Fibrillation</brief_title>
  <acronym>PROSPECT-AF</acronym>
  <official_title>PROSPective Evaluation of Outcome After CatheTer Ablation in Atrial Fibrillation : LONGITUDINAL STUDY OF PATIENTS UNDERGOING RADIOFREQUENCY ABLATION OF ATRIAL FIBRILLATION.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atrial fibrillation ablation is the most common intervention performed worldwide. Up to 20 to&#xD;
      45% of patients show recurrence of AF within 12 month after catheter ablation, however its&#xD;
      determinant are incompletely understood.&#xD;
&#xD;
      The aim of the PROSPECT-AF study is to assess the predictors of AF recurrence within the 3&#xD;
      years following ablation using clinical variables and innovative biomarkers in a prospective&#xD;
      cohort of 750 patients undergoing atrial fibrillation catheter ablation.&#xD;
&#xD;
      The secondary aims are to assess the incidence of major adverse cardiovascular outcomes&#xD;
      (MACE) and the incidence of major bleeding within the 3 years Wolfing catheter ablation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">November 2030</completion_date>
  <primary_completion_date type="Anticipated">November 2030</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of atrial fibrillation recurrence.</measure>
    <time_frame>At 3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of major adverse cardiovascular events (MACE) including hospitalization for acute heart failure, cardiovascular death, stroke, myocardial infarction</measure>
    <time_frame>At 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of major bleeding (defined by BARCâ‰¥3 bleeding)</measure>
    <time_frame>At 3 years</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">750</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Patients undergoing atrial fibrillation catheter ablation</arm_group_label>
    <description>Patients undergoing scheduled atrial fibrillation catheter ablation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>atrial fibrillation catheter ablation</intervention_name>
    <description>The ablation is performed under local anesthesia or general anesthesia. A transseptal puncture will be performed to access the left atrium. Pulmonary vein isolation will be performed as a first step. Additional lesions will be made at the discretion of the operators. Patients will receive anticoagulation for at least 3 months after the ablation. Treatment thereafter will be extended at the discretion of the treating physician.</description>
    <arm_group_label>Patients undergoing atrial fibrillation catheter ablation</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Buffy coat, plasma, serum, PBMCs&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients referred to the Lille University Hospital for schedulled Atrial fibrillation&#xD;
        catheter ablation&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient undergoing atrial fibrillation catheter ablation&#xD;
&#xD;
          -  Able to give their consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Childs&#xD;
&#xD;
          -  Patient under guardianship&#xD;
&#xD;
          -  Patients unable to give their consent&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandro Ninni, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sandro Ninni, MD</last_name>
    <phone>0320445962</phone>
    <phone_ext>+33</phone_ext>
    <email>sandro.ninni@chru-lille.fr</email>
  </overall_contact>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 16, 2021</study_first_submitted>
  <study_first_submitted_qc>August 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 18, 2021</study_first_posted>
  <last_update_submitted>August 16, 2021</last_update_submitted>
  <last_update_submitted_qc>August 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atrial fibrillation</keyword>
  <keyword>Catheter ablation</keyword>
  <keyword>Arrhythmia</keyword>
  <keyword>Biomarkers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

